Introduction <p>Myopia is a growing public health concern, particularly among young individuals. Several pharmacological and optical interventions exist to slow its progression, yet each has limitations. In January 2021, Safilens introduced the Delivery Tyro^® daily disposable contact lens, which releases hyaluronic acid, tamarind seed polysaccharide, and tyrosine, a dopamine precursor with antioxidative and cytoprotective properties.</p> Methods <p>This study analyzed post-market surveillance data collected by 55 optometrists from 241 myopic subjects (mean age, 14.73 years; mean initial spherical equivalent (SE) refraction, −&#xa0;2.72 diopters [D]) over a 12-month period of bilateral Delivery Tyro^® lens use. The purpose of the analysis was to compare the observed myopia progression in Delivery Tyro^® users with expected rates based on control SE refraction data derived from meta-analyses of similar age and ethnic cohorts.</p> Results <p>Delivery Tyro^® users experienced slower rates of myopia progression than expected. After 12 months of lens wear, the average change in SE was a −&#xa0;0.04 D compared with the expected change of −&#xa0;0.28 D from the reference control group (<i>P</i> &lt; 0.001). Furthermore, 94% of eyes exhibited no significant change in SE (defined as a change of −&#xa0;0.25 D or less).</p> Conclusions <p>These findings support the hypothesis that Delivery Tyro^® may reduce myopia progression, likely attributable to the release of tyrosine during lens wear, either due to its antioxidative properties or its role as a precursor of dopamine, a key neurotransmitter in the retina involved in visual signaling, and refractive development. Given the convenience of daily disposable lenses, Delivery Tyro^® may offer a practical solution for myopia management, particularly for young patients at elevated risk of rapid myopia progression due to genetic and environmental factors. Further confirmation of the efficacy of Delivery Tyro^® through controlled, randomized clinical trials is warranted.</p>